A PhII flop triggers an ugly rout for micro-cap biotech Aridis; Genfit CEO passes baton to successor
→ Micro-cap biotech Aridis Pharmaceuticals $ARDS got hammered this morning as investigators revealed that one of its clinical-stage drugs failed a mid-stage study, triggering safety fears and forcing the company to dump the program.
The anti-infective outfit says that AR-105 — an antibody — failed to beat out a placebo in treating ventilator-associated pneumonia caused by gram-negative Pseudomonas aeruginosa. And there was an imbalance in deaths and serious adverse events that left the therapy with a worse safety profile.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
